Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines. (Q39096231)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035472 AND SRC:MED&resulttype=core&format=json

21 February 2020

title

Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035472 AND SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035472 AND SRC:MED&resulttype=core&format=json

21 February 2020

Rosario Pinto Leite

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035472 AND SRC:MED&resulttype=core&format=json

21 February 2020

Regina Arantes-Rodrigues

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035472 AND SRC:MED&resulttype=core&format=json

21 February 2020

Palmeira C

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035472 AND SRC:MED&resulttype=core&format=json

21 February 2020

Aura Colaço

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035472 AND SRC:MED&resulttype=core&format=json

21 February 2020

Paula A. Oliveira

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035472 AND SRC:MED&resulttype=core&format=json

21 February 2020

author name string

Vítor Moreira da Silva

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035472 AND SRC:MED&resulttype=core&format=json

21 February 2020

Lúcio Lara Santos

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035472 AND SRC:MED&resulttype=core&format=json

21 February 2020

publication date

10 September 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035472 AND SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035472 AND SRC:MED&resulttype=core&format=json

21 February 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035472 AND SRC:MED&resulttype=core&format=json

21 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035472 AND SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

41.e11-22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035472 AND SRC:MED&resulttype=core&format=json

Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations

21 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Temsirolimus: a safety and efficacy review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Mtor Pathway Inhibitors in Cancer Therapy: Moving Past Rapamycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Mechanisms of mTOR inhibitor resistance in cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

The mTOR signalling pathway in human cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Phase II trial of temsirolimus in patients with metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Future directions of mammalian target of rapamycin (mTOR) inhibitor therapy in renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Effect of sirolimus on urinary bladder cancer T24 cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

The lysosomotropic agent monodansylcadaverine also acts as a solvent polarity probe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Everolimus combined with cisplatin has a potential role in treatment of urothelial bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Recent advances in treatment of advanced urothelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Mammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Common corruption of the mTOR signaling network in human tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

A mechanism for synergy with combined mTOR and PI3 kinase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Selective cytotoxicity of gemcitabine in bladder cancer cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

[Second line AUO (Working Group Urological Oncology) study AB 35/09 on metastasized urothelial carcinoma. Phase II study with RAD001 in combination with paclitaxel for patients with metastasized urothelial carcinoma of the urinary bladder after fail

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Molecular mechanisms of cisplatin resistance in bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Hallmarks of Cancer: The Next Generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

Dual Inhibition of PI3K/Akt/mTOR Pathway and Role of Autophagy in Non-Small Cell Lung Cancer Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2013.04.012

10.1016/J.UROLONC.2013.04.012

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24035472 AND SRC:MED&resulttype=core&format=json

release_wlm3pvenorgzzdfjz3dx7idqdy

21 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wlm3pvenorgzzdfjz3dx7idqdy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference